Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.

Edward B Garon Shun Lu Yasushi Goto Pedro De Marchi Luis G Paz-Ares David R Spigel Michael Thomas James Chih-Hsin YangAndrea ArdizzoniFabrice BarlesiSergey V Orlov Hiroshige YoshiokaGiannis MountziosSadhvi KhannaClaudia BossenMariana CarbiniSabine TurriAndrea MyersByoung Chul Cho

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

CANOPY-A did not show a DFS benefit of adding canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients with resected, stage II-III NSCLC. No new safety signals were identified with canakinumab.

Keyphrases

lymph node
small cell lung cancer
early stage
prognostic factors
locally advanced
advanced non small cell lung cancer
squamous cell carcinoma
clinical trial
radiation therapy
rectal cancer
chemotherapy induced